Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors
In Vivo · 2025
DOI: 10.21873/invivo.13995 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Manabu Watanabe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; mwatanabe@med.akita-u.ac.jp. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Neoplasms, Bone Density Conservation Agents, Breast Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Breast cancer frequently metastasizes to the bone, reducing quality of life and survival. Zoledronic acid (ZA), is used to treat bone metastasis; however, differences in efficacy depending on the timing of administration are not clear. This study investigated the effects of different timing of ZA administration in a mouse model of breast cancer bone metastasis. MATERIALS AND METHODS: E0771 cells (1.0×105 cells/10 μl) were injected into the femur of C57BL/6 mice to create a local bone metastasis model. The groups that started ZA administration one week before, at the same time as, one week after, and two weeks after tumor-cell administration were designated as the -1w, 0w, 1w, and 2w groups, respectively. A fifth group that did not receive ZA treatment was created as a control. ZA was administered at a dose of 100 μg/kg, and the same dose was administered once a week from the start of administration. The animals were sacrificed two and five weeks after tumor-cell administration. We evaluated body weight at the time of tumor-cell administration and sacrifice, and after sacrifice, the weight of the affected thigh, tumor volume, and bone destruction rate were determined using micro-computed tomography. Tumor necrosis and tumor growth were measured using histological immunostaining. RESULTS: Five weeks after tumor-cell administration, bone destruction rate was significantly lower in all groups compared to the control group (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; mwatanabe@med.akita-u.ac.jp.
- Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
- Department of Orthopedic Surgery, Akita Kousei Medical Center, Akita, Japan.
- Department of Orthopedic Surgery, Oomori Municipal Hospital, Akita, Japan.
Zitieren
APA
Watanabe, M., Tsuchie, H., Nagasawa, H., Hongo, M., Kasukawa, Y., Kudo, D., Kasama, F., Oya, K., Kawaragi, T., & Miyakoshi, N. (2025). Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors. In Vivo. https://doi.org/10.21873/invivo.13995
Vancouver
Watanabe M, Tsuchie H, Nagasawa H, Hongo M, Kasukawa Y, Kudo D, et al. Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors. In Vivo. 2025. doi:10.21873/invivo.13995
BibTeX
@article{Watanabe2025,
author = {Watanabe, Manabu and Tsuchie, Hiroyuki and Nagasawa, Hiroyuki and Hongo, Michio and Kasukawa, Yuji and Kudo, Daisuke and Kasama, Fumihito and Oya, Keita and Kawaragi, Takashi and Miyakoshi, Naohisa},
title = {Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.13995}
}
EUVIMED